Skip to main content
Log in

Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Our purpose was to determine the expression of the drug resistance factors multidrug resistance protein (MRP1), lung resistance protein (LRP) and P-glycoprotein (Pgp) in breast carcinoma patients treated with preoperative chemotherapy. We have studied the expression of these proteins in breast carcinomas by immunohistochemistry both prior (n = 80) and after (n = 68) preoperative chemotherapy and compared their expression with response to preoperative chemotherapy. In paired samples prior and after chemotherapy expression of drug resistance factors was significantly lower in prechemotherapy samples as compared with postchemotherapy specimens. This was observed for MRP1 (62% vs. 88%, P < 0.001), LRP (65% vs. 97%, P < 0.001) and Pgp (55% vs. 100%, P < 0.001). Prechemotherapy expression of MRP1 was more frequently observed in patients with distant metastases than in those without (50% vs. 8%, P = 0.02). No associations were observed between LRP expression and clinical parameters. Pgp expression was more frequently detected in lobular carcinomas than in ductal carcinomas (93% vs. 46%, P = 0.001) and in patients with positive lymph nodes than in patients with negative lymph nodes (65% vs. 31%, P = 0.008) but was independent of other clinical parameters. No significant associations were found between the prechemotherapy or postchemotherapy expression of either of these three proteins and response to preoperative chemotherapy. However, prechemotherapy MRP1 expression was significantly associated with shorter progression-free survival of the patients (P = 0.02), whereas no such associations were observed for either LRP or Pgp. In conclusion, preoperative chemotherapy increases the expression of MRP1, LRP and Pgp. Response to chemotherapy is not associated with pre- or postchemotherapy expression levels of these drug resistance proteins but time to progression may be influenced by prechemotherapy MRP1 expression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol 16: 93–100, 1998

    Google Scholar 

  2. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685, 1998

    Google Scholar 

  3. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz Jr AB, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483–2493, 1997

    Google Scholar 

  4. Filipits M, Suchomel RW, Dekan G, Haider K, Valdimarsson G, Depisch D, Pirker R: MRP and MDR1 gene expression in primary breast carcinomas. Clin Cancer Res 2: 1231–1237, 1996

    Google Scholar 

  5. Nooter K, Brutel de la Riviere G, Klijn J, Stoter G, Foekens J: Multidrug resistance protein in recurrent breast cancer. Lancet 349: 1885–1886, 1997

    Google Scholar 

  6. Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, Flens MJ, Klijn JGM, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 76: 486–493, 1997

    Google Scholar 

  7. Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogatko A, Leighton JC, Goldstein LJ: Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clin Cancer Res 4: 1533–1542, 1998

    Google Scholar 

  8. Ito K, Fujimori M, Nakata S, Hama Y, Shingu K, Kobayashi S, Tsuchiya S, Kohno K, Kuwano M, Amano J: Clinical signifi-cance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer. Oncol Res 10: 99–109, 1998

    Google Scholar 

  9. Filipits M, Malayeri R, Suchomel RW, Pohl G, Stranzl T, Dekan G, Kaider A, Stiglbauer W, Depisch D, Pirker R: Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res 19: 5043–5050, 1999

    Google Scholar 

  10. Pohl G, Filipits M, Suchomel RW, Stranzl T, Depisch D, Pirker R: Expression of the lung resistance protein (LRP) in primary breast cancer. Anticancer Res 19: 5051–5056, 1999

    Google Scholar 

  11. Wallner J, Depisch D, Hopfner M, Haider K, Spona J, Ludwig H, Pirker R: MDR1 gene expression and prognostic factors in primary breast carcinomas. Eur J Cancer 27: 1352–1355, 1991

    Google Scholar 

  12. Filipits M, Suchomel RW, Zöchbauer S, Malayeri R, Pirker R: Clinical relevance of drug resistance genes in malignant diseases. Leukemia 10: 10–17, 1996

    Google Scholar 

  13. Trock BJ, Leonessa F, Clarke R: Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 89: 917–931, 1997

    Google Scholar 

  14. Chevillard S, Pouillart P, Beldjord C, Asselain B, Beuzeboc P, Magdelénat H, Vielh P: Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 77: 292–300, 1996

    Google Scholar 

  15. Chung HC, Rha SY, Kim JH, Roh JK, Min JS, Lee KS, Kim BS, Lee KB: P-glycoprotein: the intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat 42: 65–72, 1997

    Google Scholar 

  16. Ro J, Sahin A, Ro JY, Fritsche H, Hortobagyi G, Blick M: Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer. Hum Path 21: 787–791, 1990

    Google Scholar 

  17. Arnal M, Franco N, Fargeot P, Riedinger J-M, Brunet-Lecomte P, Lizard-Nacol S: Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer. Breast Cancer Res Treat 61: 13–20, 2000

    Google Scholar 

  18. Vargas-Roig LM, Gago FE, Tello O, Martin de Civetta MT, Ciocca DR: c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 84: 129–134, 1999

    Google Scholar 

  19. Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB, Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71: 787–795, 1997

    Google Scholar 

  20. Schneider J, Gonzalez-Roces S, Pollán M, Lucas R, Tejerina A, Martin M, Alba A: Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 3: 183–191, 2001

    Google Scholar 

  21. Yang X, Uziely B, Groshen S, Lukas J, Israel V, Russell C, Dunnington G, Formenti S, Muggia F, Press MF: MDR1 gene expression in primary and advanced breast cancer. Lab Invest 79: 271–280, 1999

    Google Scholar 

  22. Faneyte IF, Kristel PM, and van de Vijver MJ: Determining MDR1/P-glycoprotein expression in breast cancer. Int J Cancer 93: 114–122, 2001

    Google Scholar 

  23. Lizard-Nacol S, Genne P, Coudert B, Riedinger J-M, Arnal M, Sancy C, Brunet-Lecomte P, Fargeot P: MDR1 and thymidilate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 19: 3575–3582, 1999

    Google Scholar 

  24. Kickhoefer VA, Rajavel KS, Scheffer GL, Dalton WS, Scheper RJ, Rome LH: Vaults are up-regulated in multidrugresistant cancer cell lines. J Biol Chem 273: 8971–8974, 1998

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rudas, M., Filipits, M., Taucher, S. et al. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy. Breast Cancer Res Treat 81, 149–157 (2003). https://doi.org/10.1023/A:1025751631115

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025751631115

Navigation